266 related articles for article (PubMed ID: 21412886)
1. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.
Oliveri RS; Wetterslev J; Gluud C
Cochrane Database Syst Rev; 2011 Mar; (3):CD004787. PubMed ID: 21412886
[TBL] [Abstract][Full Text] [Related]
2. The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011.
Ray CE; Haskal ZJ; Geschwind JF; Funaki BS
J Vasc Interv Radiol; 2011 Dec; 22(12):1693-6. PubMed ID: 22035882
[TBL] [Abstract][Full Text] [Related]
3. Microwave coagulation for liver metastases.
Storman D; Swierz MJ; Mitus JW; Pedziwiatr M; Liang N; Wolff R; Bala MM
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD010163. PubMed ID: 38534000
[TBL] [Abstract][Full Text] [Related]
4. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails.
Wang G; Zhang J; Liu H; Zheng Q; Sun P
BMC Gastroenterol; 2024 Jun; 24(1):195. PubMed ID: 38849765
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.
Long J; Zhang X; Mi W; Shi J; Ren H; Wang Q
Aging (Albany NY); 2024 Jan; 16(1):389-401. PubMed ID: 38189812
[TBL] [Abstract][Full Text] [Related]
6. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis.
Tai E; Kennedy S; Farrell A; Jaberi A; Kachura J; Beecroft R
Curr Oncol; 2020 Dec; 27(6):e537-e546. PubMed ID: 33380868
[TBL] [Abstract][Full Text] [Related]
7. Compound Kushen injection combined with transarterial chemoembolization for hepatocellular carcinoma: An evidence map and overview of systematic reviews.
Lu T; Kong B; Wang Y; Yu J; Pan Y; Chen D; Li H; Chen X; Yuan Z; Yang Z; Zhang J; Ding T; Zhang G; Fan Q; Wang X
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117267. PubMed ID: 37838291
[TBL] [Abstract][Full Text] [Related]
8. A Rare Early-Onset Fatal Complication after Transarterial Chemoembolization: A Case Report and Review of the Literature.
Péčová M; Benko J; Péč MJ; Jurica J; Horná S; Bolek T; Hurtová T; Sýkora J; Zeleňák K; Samoš M; Sokol J
Curr Oncol; 2024 Apr; 31(4):1961-1970. PubMed ID: 38668050
[TBL] [Abstract][Full Text] [Related]
9. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
[TBL] [Abstract][Full Text] [Related]
10. Transarterial embolization followed by staged hepatectomy versus emergency hepatectomy for ruptured HCC: a meta-analysis.
Pan T; Gao F; Huang X; Xu X
Clin Transl Oncol; 2024 Jan; 26(1):155-170. PubMed ID: 37328589
[TBL] [Abstract][Full Text] [Related]
11. Impact of anticancer drugs on the therapeutic efficacy and side effects of hepatic arterial embolization for hepatocellular carcinoma.
Ihira H; Sonomura T; Makitani A; Makitani K; Fukuda K; Tanaka R; Koyama T; Sato H; Wan K; Ueno M; Ida Y; Kawai N; Minamiguchi H
JGH Open; 2023 Dec; 7(12):884-888. PubMed ID: 38162847
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis on the Therapeutic Effect of Transcatheter Arterial Chemoembolisation Combined with Portal Vein Embolisation.
Liu XJ; Song PW; Wang LG; Zou HN; Zhang LL
Chemotherapy; 2024 May; ():. PubMed ID: 38797169
[TBL] [Abstract][Full Text] [Related]
13. Monitoring rules for stopping accrual in comparative survival studies.
Rubinstein LV; Gail MH
Control Clin Trials; 1982 Dec; 3(4):325-43. PubMed ID: 7160190
[TBL] [Abstract][Full Text] [Related]
14. Chemoembolization for intermediate HCC: is there proof of survival benefit?
Forner A; Llovet JM; Bruix J
J Hepatol; 2012 Apr; 56(4):984-6. PubMed ID: 22008737
[TBL] [Abstract][Full Text] [Related]
15. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
;
J Hepatol; 2012 Apr; 56(4):908-43. PubMed ID: 22424438
[No Abstract] [Full Text] [Related]
16. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
18. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.
Xie ZB; Ma L; Wang XB; Bai T; Ye JZ; Zhong JH; Li LQ
Tumour Biol; 2014 Sep; 35(9):8451-9. PubMed ID: 25038916
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis.
Zhang Y; Li Y; Ji H; Zhao X; Lu H
Biosci Trends; 2015 Oct; 9(5):289-98. PubMed ID: 26559021
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria.
Rong G; Bai W; Dong Z; Wang C; Lu Y; Zeng Z; Qu J; Lou M; Wang H; Gao X; Chang X; An L; Li H; Chen Y; Hu KQ; Yang Y
PLoS One; 2015; 10(4):e0123065. PubMed ID: 25849963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
